Method and tool for predicting cancer and other diseases
AssigneeHvidovre Hospital
InventorsJesper Eugen-Olsen, Steen B. Haugaard, Ove Andersen
Life of this patent
Estimating the term…
Abstract
The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.
Claims20
A method for diagnosing low-grade inflammation and/or metabolic syndrome in a mammalian subject, in particular, a human subject, comprising:
- (a) performing an in vitro measurement of the level of a marker in the form of soluble urokinase plasminogen activator receptor (suPAR), in one or more samples comprising a biological fluid derived from said subject, and
- (b) using the one or more measurement value obtained as a factor in the diagnosis of low-grade inflammation related disease and/or metabolic syndrome.
2-3. (canceled)
A method for detecting the level of low-grade inflammation and/or metabolic syndrome in a mammalian subject comprising:
- (a) isolating a sample from a subject;
- (b) measuring the level of a marker in the form of (i) soluble urokinase plasminogen activator receptor (suPAR), and/or (ii) D2D3 cleavage products of suPAR in said sample of (a);
- (c) comparing the measurement obtained in step (b) with a reference value, wherein an increase in the level of said marker in said sample indicates increased low-grade inflammation and/or the presence of metabolic syndrome.
18-28. (canceled)
A method for monitoring the treatment of low-grade inflammation and/or metabolic syndrome in a mammalian subject comprising:
- (a) isolating a sample from a subject undergoing treatment for low-grade inflammation and/or metabolic syndrome;
- (b) measuring the level of a marker in the form of (i) soluble urokinase plasminogen activator receptor (suPAR), (ii) and/or D2D3 cleavage products of suPAR,
- wherein a decrease in the level of said marker used in step (b) is an indication of progression of treatment.
31-71. (canceled)
Dependencies are inferred from the claim text.